A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL
This study is testing a new medication called olverembatinib combined with chemotherapy for adults with a fast-growing blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia. Researchers want to see if this new combination works better and is safer than standard treatments currently chosen by doctors.
You might be able to join if you have been recently diagnosed with this specific type of blood cancer, have good liver and kidney function, and are expected to live for at least three months. People with certain conditions, like leukemia that has spread to the brain or a history of other specific blood cancers, cannot participate.
Participants will be randomly assigned to receive either the new study drug, olverembatinib, or a standard targeted therapy medication, both combined with chemotherapy. Your health and the response of the cancer will be closely monitored by the study team throughout the process.
This study is currently recruiting patients at multiple medical centers, including locations in Birmingham, Alabama, and Duarte and Los Angeles, California. You can talk to your care team to see if one of these locations is convenient for you.
- 1Testing a new cancer drug called olverembatinib with chemotherapy
- 2Comparing the new treatment against standard care options
- 3Currently recruiting participants at select locations in the United States
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.